RxDoctor Payments Data

Douglas Schechter, MD

Anesthesiology · Manhasset, NYNPI 1588963888

Payments from drug & device makers

$12,340in general payments, 2019–2025

Across 631 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Abbott$2K
  • Scilex Pharmaceuticals Inc.$1K
  • Vertos Medical, Inc.$827
  • Collegium Pharmaceutical, Inc.$684
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$449
  • plus $5K from 48 others

What the payments were for

  • Travel & lodging$2202%
  • Food & beverage$12,11998%
  • Education$10%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,340 in reported general payments places this provider in the 95th percentile of 4,157 anesthesiology providers in New York.

See all anesthesiology providers in New York

Medicare billing

Part B allowed, 2024
$540,643
Medicare patients
1,090
Services billed
8,080

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen378$36,030
Nucynta ErTapentadol Hcl17$22,275
MovantikNaloxegol Oxalate32$12,877
BelbucaBuprenorphine Hcl15$11,741
Xtampza ErOxycodone Myristate21$10,721
OxycontinOxycodone Hcl26$7,872
Oxycodone Hcl358$7,790
Pregabalin161$4,589
Lidocaine65$4,442
Fentanyl39$3,545
Naloxone Hcl54$3,493
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen113$2,784
Gabapentin277$2,777
Tizanidine Hcl237$2,472
Tramadol Hcl209$1,904

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta Er, Belbuca, Xtampza Er$684$44,73753 claims
Redhill Biopharma Inc.Movantik$131$12,87732 claims
Hikma Pharmaceuticals USAMorphine Sulfate$32$1,37727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,157 anesthesiology providers in New York.

Other anesthesiology in Manhasset

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →